Comparison
GHK-Cu Topical vs Injectable: 10x Absorption Gap Topical GHK-Cu has decades of clinical data; injectable has none in humans. Which route fits which goal -- and when do both make s…
View details →
Comparison
BPC-157 VEGF upregulation, angiogenesis promotion, fibroblast activation Tendons, ligaments, muscle, GI mucosa 250–500 mcg daily subcutaneous or oral Lyophilized: −20°C; Reconstit…
View details →
Comparison
BPC-157 Promotes fibroblast migration and collagen synthesis via VEGF upregulation 250–500mcg per injection Daily for 4–6 weeks Tendon, ligament, muscle tears. Acute and subacute …
View details →
Comparison
BPC-157 VEGFR-2 agonist. Promotes angiogenesis and fibroblast recruitment Tendon, ligament, and low-vascular-density injuries 200–500 mcg per dose, daily or twice daily Start with…
View details →
Comparison
Let's get specific about when to use each.
View details →
Comparison
This table summarizes the three peptides with the strongest biological rationale and most extensive (though still limited) evidence base for injury prevention research in 2026. BP…
View details →